A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Condition:   Hepatic Impairment Intervention:   Drug: Enasidenib Sponsor:   Celgene Not yet recruiting - verified September 2017

Source: ClinicalTrials.gov - September 19, 2017 Category: Research Source Type: clinical trials